A 23-year-old woman developed ischemic stroke (IS) 8 to 12 hours after ingestion of sumatriptan (ST) and then developed mucosal bleeding secondary to acute thrombocytopenia likely due to dipyridamole (DP) on the 10th day poststroke. Sumatriptanassociated IS and DP-induced thrombocytopenia are rare events in themselves and their sequential occurrence in the same patient is quite exceptional. We compare our case to other similar cases in the literature.
Introduction
Sumatriptan (ST) is a selective 5-hydroxytryptamine receptor agonist meant to abort migraine attacks by reversing intracranial vasodilatation that underscores migraine. 1 Dipyridamole (DP) is a phosphodiesterase inhibitor that increases the intraplatelet levels of cyclic adenosine monophosphate and cyclic guanine monophosphate, which in turn reversibly inhibit platelet aggregation. The antithrombotic effect of DP relies on this mechanism, though an effect on vascular production of nitric oxide and on antioxidant mechanisms are also advocated. 2 We report on a young Indian lady who suffered an ischemic stroke (IS) 8 to 12 hours after the ingestion of ST and who went on to develop acute thrombocytopenia almost 2 weeks later after the ingestion of DP and compare our case to similar cases in the literature.
Case Report
A 23-year-old Indian mother of 2 was presented to accident and emergency for paresthesia and weakness in the right upper limb. The previous morning she developed a headache that had increased in severity over time. Because it was not relieved by paracetamol, her pharmacist recommended ST. The patient took one 25-mg tablet at 2 PM and another at 6 PM. Because there was no relief from the second tablet and because of the development of weakness in the right hand and forearm, she was presented to the casualty. Her English was limited and the history was taken from her husband. Apart from experiencing intermittent headaches of a lesser severity for approximately 6 months, she had always been in good health. Her family history revealed an IS in her father at the age of 60 years. All her 5 younger siblings were in good health. The patient was distressed, nauseous, and slightly febrile at 37.6 C. She had neither photophobia nor rashes. Examination was unremarkable but for a decreased grip in her right hand. The initial blood tests were all normal. A magnetic resonance imaging (MRI) of brain revealed a recent infarct in the left temporal-parietal junction. The echocardiogram and the carotid Doppler ultrasound were normal.
She was started on aspirin 300 mg with the instruction of decreasing it to 75 mg on the 10th day of treatment and to add DP 200 mg at the same time. The day after starting DP, she presented to primary care with bleeding gums and was referred to hematology. Her platelet count was 0 Â 10 9 /L. The possibility of drug-induced thrombocytopenia secondary to DP was entertained, though oral prednisolone was started at 50 mg daily for 7 days, tapered down by 10 mg every 3 days. After completing almost 3 weeks of steroids, her platelet count returned to 153 Â 10 9 /L. Weakness in her right hand had improved but paresthesias persisted. A thrombophilia screen including antithrombin, protein C, protein S, activated protein C, prothrombin mutation 20210, antiphospholipid antibodies, and homocysteine was negative. It was concluded that her stroke was most likely secondary to ST and her thrombocytopenia secondary to DP.
Discussion
The occurrence of IS after ST intake is quite rare, but several cases [3] [4] [5] [6] [7] have been described so far (Table 1) . With the exception of the first case in Table 1 , all cerebrovascular events occurred within 24 hours of intake of the offending drug and in almost all patients, the symptoms improved or resolved barring the fatal case in the study of Jayamaha and Street, whose left cerebellar infarction was complicated by obstructive hydrocephalus. Other cases of cerebral vasoconstriction have occurred in patients taking other serotonergic drugs. 8 A survey on 12 339 migraineurs taking ST revealed 6 cases of IS but in only 2 it developed soon after the subcutaneous injection of the drug. 9 A case-control study comparing 13 602 ST-treated migraine patients to 27 221 nonmigraine controls failed to find an association between ST use and IS, 10 with an adjusted (hypertension, diabetes, obesity, hyperlipidemia, contraceptive use, and smoking) hazard ratio of 1.13. A subsequent case-control study confirmed the previous findings 11 whereas no association between nasal ST (20 mg) and IS was found in an emergency setting. 12 Similarly, zolmatriptan was not associated with IS in an adolescent population. 13 These figures, coupled to the few case reports, suggest that IS following triptans is really a rare occurrence. The pathogenesis of cerebrovascular events in this setting must rely on the selective vasoconstriction of cerebral arteries induced by triptans given that there is a relationship between vasoconstrictor potency in cerebral arteries and clinically relevant plasma levels of triptans. 14 Our patient also developed mucosal bleeding on the 11th day of antiplatelet treatment: the close temporal onset of acute thrombocytopenia on dypyridamole administration is in favor of a drug-induced effect, though the combined effect of both drugs might have prompted the bleeding that continued because of the thrombocytopenia. A systematic review of case reports did not find dypyridamole among the medications inducing acute thrombocytopenia 15 as confirmed by a recent update. 16 However, an earlier epidemiological case-control survey of patients in Massachusetts, Rhode Island, and Philadelphia showed that during each week of exposure, dypyridamole caused thrombocytopenia in 3.9 of every 1 million users (relative risk 14), with a faster onset of thrombocytopenia compared to other offending drugs. 17 Our patient, therefore, developed 2 very serious iatrogenic conditions, passing from thrombosis to bleeding in less than 3 weeks: the obvious differential diagnosis included the antiphospholipid syndrome that may clinically present with thrombosis and may be complicated by thrombocytopenia 18 : this was ruled out by the lack of antiphospholipid antibodies in plasma. Of note, our patient had not been seen by a neurologist for her previous headaches and ST had been recommended by a pharmacist who had never seen the patient. We believe that any patient with a persistent headache should be seen by a general practitioner and/or a neurologist and that a drug such as ST should not be recommended lightly by a nonmedical professional, given its potential side effects but should always be released under specific physician's orders.
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